SCHEMBL1801345

SCHEMBL1801345

COC(=O)c1ccc(CN2C(=O)CNC23CCN(C(=O)Cc2ccccc2)CC3)cc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
ALDH1A1 P00352 3/20 0.45
OPRD1 P41143 2/20 0.45
OPRK1 P41145 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
LMNA P02545 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
GPR183 P32249 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5152604 0.89 HDAC1 (0.45) MEN1KMT2AALDH1A1OPRD1SMN1; SMN2
SCHEMBL4038092 0.83 ALDH1A1 (0.46) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL1803525 0.82 NPC1 (0.44) MEN1KMT2AALDH1A1OPRD1OPRK1
SCHEMBL1797571 0.82 LMNA (0.44) MEN1KMT2AKDM4ELMNAL3MBTL1
SCHEMBL3920891 0.81 LMNA (0.44) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL1798663 0.81 LMNA (0.45) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL1803273 0.81 MEN1 (0.47) MEN1KMT2AALDH1A1OPRD1OPRK1
SCHEMBL1799853 0.79 OPRD1 (0.46) MEN1KMT2AALDH1A1OPRD1OPRK1
SCHEMBL1801939 0.79 OPRD1 (0.47) OPRD1OPRK1LMNANPC1HTT
SCHEMBL1798596 0.78 SMN1; SMN2 (0.49) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US claimed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US disclosed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 MEN1 1474/4885KMT2A 4267/4885ALDH1A1 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.